Toleranzia AB takes an important step towards patent granting in Europe

26 January - 2016

In connection with a so-called “Intention to Grant Notice”, which was previously received from the European Patent Office (EPO), Toleranzia AB today announces its decision to move forward with European Patent Application No. 11836713, regarding the company’s tolerogen platform for the treatment of autoimmune diseases. The decision means that the company approves the changes in the patent text as proposed by the EPO, and that translations of the claims into French and German are made. These measures are a prerequisite for final approval, which the company expects will occur during 2016.

Bjorn Löwenadler, CEO, comments
Europe is potentially a large future market for our platform technology and therefore we are very happy that the process towards approval in Europe has taken an important step forward.

For further information about Toleranzia AB, please contact:
Björn Löwenadler, CEO
Phone: +46 70-631 00 30
E-mail: bjorn.lowenadler@toleranzia.com

About the company
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.